Merck & Company (MRK) Stock Price, Quote & News

Company Profile

Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. The company also provides veterinary pharmaceuticals, vaccines and health manageme...

Industry: Drug Manufacturers - General

Sector: Healthcare

Phone: 908 740 4000

Website: www.merck.com

Address:

126 East Lincoln Avenue, Rahway, United States

mv21970 May. 22 at 6:59 PM

$BHVN everyone is (understandably) waiting for data/news on degraders, epilepsy, and obesity, but today's $MRK and $AZN news shows how Trop2-ADCs can help in cancer treatment, and with BHV-1510, Biohaven has, imo, another potential blockbuster in the pipeline

0 · Reply

ProfitWhisperer May. 22 at 5:57 PM

thin float. CSE halted. naked short positions built across OTC and Frankfurt. Ebola narrative shifted. May 31 filing is the trigger. $BVAXF $MRK $AEMD $EBS $REGN

0 · Reply

ProfitWhisperer May. 22 at 5:57 PM

BioVaxys acquired IMV's entire IP portfolio in 2024. that includes the DPX Ebola NIH data. they own the foundation to build on. $BVAXF $MRK $AEMD $EBS $REGN

0 · Reply

ProfitWhisperer May. 22 at 5:55 PM

two dose regimen. day 0 and day 56. challenge on day 70. $BVAXF BioVaxys DPX Ebola vaccine gave full protection within that window. $MRK $AEMD $EBS $REGN

0 · Reply

ProfitWhisperer May. 22 at 5:47 PM

NIAID ran the study under their preclinical services program. not BioVaxys running their own tests. independent NIH infrastructure validating DPX Ebola results. $BVAXF $MRK $AEMD $EBS $REGN

0 · Reply

Davidendz May. 22 at 5:28 PM

Ebola news + $BVAXF dropping their strong DPX monkey study (full protection!) = potential volume spike and quick re-rating for the stock right now. Smart timing that puts $BVAXF back on the radar alongside $MRK $REGN $EBS $AEMD.

0 · Reply

Davidendz May. 22 at 5:26 PM

Expect a surge in attention, trading volume, and share price momentum as the market wakes up to this hidden platform gem $BVAXF $MRK $REGN $EBS $AEMD.

0 · Reply

Davidendz May. 22 at 5:24 PM

$BVAXF revisiting Ebola vaccine study: monkeys received DPX formulation, challenged day 70 with wild-type lethal virus. 100 percent survival, no symptoms. Controls dead in 7 days. DRC emergency now $MRK $AEMD $EBS $REGN $BVAXF

0 · Reply

william2012 May. 22 at 4:48 PM

$MRK damn Ebola outbreak.

0 · Reply

Diefreeandsell May. 22 at 4:41 PM

$IBRX Thanks for history lesson but there is a huge BCG shortage and the tokyo bcg has shown it is equivalent to if not superior to $MRK 's Tice BCG. It is in PH3 clinical trials and ready for a co like IBRX to submit to FDA for approval much faster than SII rBCG will be ready. You know Merck had 14 years to fix the shortage prob and look who had to fix it, Doc PSS. They'll make it sooner than you expect as spotlight and microscope are now on FDA get it done, patients and doctors are clamoring for it.

1 · Reply

Merck stock jumps as Keytruda combo trials boost cancer pipeline

May 22, 2026, 10:23 AM EDT - 4 hours ago

Merck Stock Climbs on Cancer Data. Why the Drugmaker Is More Than a One-Trick Pony.

2026-05-22T12:14:22.000Z - 6 hours ago

Merck receives positive CHMP opinion for KEYTRUDA plus Padcev

May 22, 2026, 7:55 AM EDT - 7 hours ago

Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as Perioperative Treatment for Adults With Cisplatin-Ineligible Resectable Muscle-Invasive Bladder Cancer

May 21, 2026, 5:06 PM EDT - 21 hours ago

Kelun, Merck's lung cancer combo improves survival in late-stage China trial

May 21, 2026, 5:03 PM EDT - 21 hours ago

Moderna, Merck cancer combo cuts melanoma spread risk at five years

MRNA

May 21, 2026, 8:00 AM EDT - 1 day ago

Merck Announces First Patient Dosed in Phase 3 Study for Investigational Antibody-Drug Conjugate in Colorectal Cancer

May 20, 2026, 11:00 AM EDT - 2 days ago

National Advertising Review Board Refers Merck Animal Health to FTC and FDA for Bravecto Quantum Dosing Claims

2026-05-19T12:20:29.000Z - 3 days ago

Exelixis announces clinical development collaboration with Merck

EXEL

2026-05-18T10:52:46.000Z - 4 days ago

Merck’s Sac-TMT met primary endpoints in endometrial cancer trial

May 18, 2026, 6:51 AM EDT - 4 days ago

Merck's endometrial cancer drug meets late-stage trial goals

May 18, 2026, 6:45 AM EDT - 4 days ago

Merck Announces TroFuse-005 Trial Evaluating Sacituzumab Tirumotecan (Sac-TMT) Met Primary Endpoints of Overall Survival (OS) and Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer

May 12, 2026, 6:45 AM EDT - 10 days ago

Merck Highlights New Long-Term Data and Advancements Across Broad Oncology Portfolio and Pipeline Research at ASCO 2026

2026-05-11T17:32:53.000Z - 11 days ago

Erasca enters AURORAS-1 clinical trial pact, supply agreement with Merck

ERAS

May 7, 2026, 2:05 PM EDT - 15 days ago

Merck Scientists Publish Landmark Paper on Novel Method for Large-Scale Biocatalytic Synthesis of Investigational Oral PCSK9 Inhibitor, Enlicitide Decanoate

2026-05-07T10:31:01.000Z - 15 days ago

Merck reinstated with a Neutral at Citi

May 6, 2026, 9:00 AM EDT - 16 days ago

Merck Animal Health Selects Salesforce's Agentforce Life Sciences for Customer Engagement to Transform Animal Care and Enhance Support Experiences for Employees

CRM

May 5, 2026, 8:45 AM EDT - 17 days ago

Merck Completes Acquisition of Terns Pharmaceuticals, Inc.

TERN

May 4, 2026, 4:56 PM EDT - 17 days ago

Merck (MRK) Price Forecast: Double Top Signals Deeper Correction Risk

Apr 30, 2026, 9:00 AM EDT - 22 days ago

Merck & Co. Earnings Call Transcript: Q1 2026

Apr 30, 2026, 9:00 AM EDT - 22 days ago

Merck & Co. Earnings release: Q1 2026

Apr 30, 2026, 9:00 AM EDT - 22 days ago

Merck & Co. Slides: Q1 2026

Apr 30, 2026, 9:00 AM EDT - 22 days ago

Merck & Co. Quarterly report: Q1 2026

Apr 30, 2026, 8:05 AM EDT - 22 days ago

Merck Announces First Dose in Phase 3 Study with Enpatoran for Lupus Patients with Active Skin Manifestations

Apr 30, 2026, 6:51 AM EDT - 22 days ago

Merck Sales Rise on Continued Keytruda Growth

Apr 30, 2026, 6:32 AM EDT - 22 days ago

Merck beats quarterly estimates on strength of Keytruda and new products, narrows outlook

Apr 30, 2026, 6:31 AM EDT - 22 days ago

Merck posts quarterly loss due to Cidara charge, sales rise 5%

Apr 30, 2026, 6:30 AM EDT - 22 days ago

Merck & Co., Inc., Rahway, N.J., USA Announces First-Quarter 2026 Financial Results; Highlights Significant Regulatory Approvals and Clinical Milestones

Apr 28, 2026, 6:45 AM EDT - 24 days ago

Merck's Playing with Heart Program Teams Up With Professional Baseball Clubs and Baseball Legends to Help Raise Awareness About LDL-C, Called “Bad” Cholesterol, and How It May Impact the Risk of Heart Attack or Stroke

Apr 24, 2026, 6:45 AM EDT - 4 weeks ago

Merck Announces Expiration of Hart-Scott-Rodino Act Waiting Period to Acquire Terns Pharmaceuticals, Inc.

TERN

Apr 22, 2026, 8:00 AM EDT - 4 weeks ago

Merck and Google Cloud Partner to Accelerate Agentic AI Enterprise Transformation

Apr 22, 2026, 7:02 AM EDT - 4 weeks ago

Merck to partner with Google Cloud on AI initiatives

GOOG GOOGL

Apr 22, 2026, 7:02 AM EDT - 4 weeks ago

Exclusive: Merck, rivals eye deal for Inhibrx experimental cancer drug tied to Keytruda, sources say

INBX

Apr 21, 2026, 2:11 PM EDT - 4 weeks ago

FDA Approves Merck's Once-Daily IDVYNSO™ (doravirine/islatravir)

Apr 21, 2026, 11:53 AM EDT - 4 weeks ago

US FDA approves Merck's combination HIV treatment

Apr 21, 2026, 6:53 AM EDT - 4 weeks ago

Merck-Eisai's combination cancer therapy fails to meet main goals of late-stage study

Apr 21, 2026, 6:45 AM EDT - 4 weeks ago

Merck and Eisai Provide Update on Phase 3 LITESPARK-012 Trial Evaluating First-Line Combination Treatments for Certain Patients With Advanced Renal Cell Carcinoma (RCC)

Apr 20, 2026, 6:48 AM EDT - 4 weeks ago

FDA Grants Priority Review for KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each with Padcev® (enfortumab vedotin-ejfv), for Cisplatin-Eligible Patients with Muscle-Invasive Bladder Cancer

Apr 17, 2026, 7:49 AM EDT - 5 weeks ago

European Commission Approves Merck's ENFLONSIA™ (clesrovimab) for the Prevention of Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease in Infants During Their First RSV Season

Apr 13, 2026, 7:00 AM EDT - 5 weeks ago

Ifinatamab Deruxtecan Granted Priority Review in the U.S. for Adult Patients with Previously Treated Extensive-Stage Small Cell Lung Cancer who Experienced Disease Progression on or After Platinum-Based Chemotherapy

Apr 10, 2026, 2:20 PM EDT - 6 weeks ago

1Q26 Earnings: Where Street Estimates Are Too Low & Who Should Beat

Apr 8, 2026, 8:00 AM EDT - 6 weeks ago

Merck & Co. Proxy statement: Proxy filing

Apr 8, 2026, 8:00 AM EDT - 6 weeks ago

Merck & Co. Proxy statement: Proxy filing

Apr 7, 2026, 9:00 AM EDT - 6 weeks ago

Merck Begins Tender Offer to Acquire Terns Pharmaceuticals, Inc.

TERN

Apr 5, 2026, 10:41 AM EDT - 6 weeks ago

Merck Just Made a Big Bet on a New Cancer Growth Engine

Apr 3, 2026, 11:08 AM EDT - 7 weeks ago

Swiss industry body says US tariffs on pharmaceuticals will harm patients

ABBV AMGN AZN BMY NVO

Apr 2, 2026, 5:34 PM EDT - 7 weeks ago

Trump Administration Unveils Up to 100% Tariff on Branded Drugs

AZN NVO ABBV AMGN BMY

Apr 2, 2026, 5:33 PM EDT - 7 weeks ago

Trump threatens 100% tariff on US drug makers that don't strike deals to lower prices

ABBV AMGN AZN BMY NVO

Apr 2, 2026, 3:29 PM EDT - 7 weeks ago

Drugmakers face 100% tariff unless they cut prices or produce drugs in US

AZN NVO ABBV AMGN BMY

Apr 2, 2026, 2:59 PM EDT - 7 weeks ago

Global pharma companies that have publicly announced Trump drug pricing agreements

ABBV AMGN AZN BMY

Apr 2, 2026, 6:50 AM EDT - 7 weeks ago

Merck Announces Initiation of Pivotal Phase 2b/3 Trial Evaluating MK-8748 (Tiespectus), an Investigational Bispecific Tie2 Agonist/VEGF Inhibitor, for the Treatment of Neovascular Age-Related Macular Degeneration

Apr 2, 2026, 6:45 AM EDT - 7 weeks ago

European Commission Approves KEYTRUDA® (pembrolizumab) Plus Paclitaxel ± Bevacizumab for the Treatment of Adults With PD-L1 (CPS ≥1) Platinum-Resistant Recurrent Ovarian Carcinoma Who Have Received One or Two Prior Systemic Treatment Regimens

Apr 1, 2026, 7:00 AM EDT - 7 weeks ago

Merck to Hold First-Quarter 2026 Sales and Earnings Conference Call April 30

Mar 31, 2026, 9:56 AM EDT - 7 weeks ago

Barclays names top 4 defensive stocks to weather global uncertainty

EXR JPM KO

Mar 31, 2026, 9:13 AM EDT - 7 weeks ago

Infinimmune, Merck enter into antibody discovery pact

Mar 31, 2026, 8:00 AM EDT - 7 weeks ago

Infinimmune Enters Collaboration with Merck to Discover Novel Human Antibody Therapeutics

Mar 30, 2026, 11:54 AM EDT - 7 weeks ago

Merck's drug reduced bad cholesterol by 64.6% in late-stage trial

Mar 30, 2026, 11:45 AM EDT - 7 weeks ago

Merck's Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Demonstrated Significantly Greater LDL-C Reductions at Eight Weeks Compared to Guideline-Recommended Oral Non-Statin Therapies When Added to Background Statins

Mar 25, 2026, 8:00 AM EDT - 2 months ago

Merck & Co. Transcript: M&A announcement

Mar 25, 2026, 8:00 AM EDT - 2 months ago

Merck & Co. Press release: M&A announcement

Mar 25, 2026, 8:00 AM EDT - 2 months ago

Merck & Co. Slides: M&A announcement

Mar 25, 2026, 7:35 AM EDT - 2 months ago

Merck makes a big move into new cancer treatments with a $6.7 billion buyout deal

Mar 25, 2026, 7:14 AM EDT - 2 months ago

Merck to buy Terns Pharmaceuticals for $6.7 billion to boost cancer pipeline

TERN

mv21970 May. 22 at 6:59 PM

0 · Reply

ProfitWhisperer May. 22 at 5:57 PM

thin float. CSE halted. naked short positions built across OTC and Frankfurt. Ebola narrative shifted. May 31 filing is the trigger. $BVAXF $MRK $AEMD $EBS $REGN

0 · Reply

ProfitWhisperer May. 22 at 5:57 PM

BioVaxys acquired IMV's entire IP portfolio in 2024. that includes the DPX Ebola NIH data. they own the foundation to build on. $BVAXF $MRK $AEMD $EBS $REGN

0 · Reply

ProfitWhisperer May. 22 at 5:55 PM

two dose regimen. day 0 and day 56. challenge on day 70. $BVAXF BioVaxys DPX Ebola vaccine gave full protection within that window. $MRK $AEMD $EBS $REGN

0 · Reply

ProfitWhisperer May. 22 at 5:47 PM

NIAID ran the study under their preclinical services program. not BioVaxys running their own tests. independent NIH infrastructure validating DPX Ebola results. $BVAXF $MRK $AEMD $EBS $REGN

0 · Reply

Davidendz May. 22 at 5:28 PM

0 · Reply

Davidendz May. 22 at 5:26 PM

Expect a surge in attention, trading volume, and share price momentum as the market wakes up to this hidden platform gem $BVAXF $MRK $REGN $EBS $AEMD.

0 · Reply

Davidendz May. 22 at 5:24 PM

0 · Reply

william2012 May. 22 at 4:48 PM

$MRK damn Ebola outbreak.

0 · Reply

Diefreeandsell May. 22 at 4:41 PM

1 · Reply

ProfitWhisperer May. 22 at 4:13 PM

wild type Zaire strain. the deadliest Ebola species. $BVAXF BioVaxys DPX vaccine protected all four monkeys against it. controls all died. $MRK $AEMD $EBS $REGN

0 · Reply

wheresdannynow May. 22 at 4:06 PM

Breaking Ebola concerns in DRC. $BVAXF has historical DPX data showing full protection against lethal Ebola in primates after just 2 doses. Study partners NIH/NIAID $MRK $AEMD $EBS $REGN $BVAXF

0 · Reply

wheresdannynow May. 22 at 4:04 PM

$BVAXF looking into prior DPX-Ebola vaccine that gave 100 percent survival in lethal monkey challenge. Timing lines up with current DRC public health emergency. Eyes on $MRK $AEMD $EBS $REGN $BVAXF

0 · Reply

wheresdannynow May. 22 at 4:03 PM

All vaccinated monkeys alive and healthy more than 2 weeks post lethal dose. Controls died fast $MRK $AEMD $EBS $REGN $BVAXF

0 · Reply

wheresdannynow May. 22 at 4:02 PM

Study showed complete protection in primates versus wild-type lethal Ebola. Strong data $MRK $AEMD $EBS $REGN $BVAXF

0 · Reply

ProfitWhisperer May. 22 at 3:28 PM

DepoVax was the original name for DPX. IMV ran the Ebola study. $BVAXF BioVaxys acquired IMV and all its IP including this Ebola data. $MRK $AEMD $EBS $REGN

0 · Reply

ProfitWhisperer May. 22 at 3:24 PM

$BVAXF $MRK $AEMD $EBS $REGN

0 · Reply

Ventureville May. 22 at 3:21 PM

No symptoms more than 2 weeks later. DRC news heating up. $BVAXF watching this closely $MRK $AEMD $EBS $REGN $BVAXF

0 · Reply

ProfitWhisperer May. 22 at 3:20 PM

750 suspected cases, 177 suspected deaths, WHO risk level raised to very high nationally. BioVaxys announced today they are actively looking at their Ebola program. $BVAXF $MRK $AEMD $EBS $REGN

0 · Reply

ProfitWhisperer May. 22 at 3:20 PM

38% test positivity. outbreak still expanding. BDBV spreading across borders. BioVaxys revisiting DPX Ebola program. $BVAXF $MRK $AEMD $EBS $REGN

0 · Reply

Ventureville May. 22 at 3:20 PM

$BVAXF 2 doses gave full protection versus lethal wild-type virus in primates. Controls died fast. This could be key $MRK $AEMD $EBS $REGN $BVAXF

0 · Reply

Ventureville May. 22 at 3:16 PM

DPX-formulated vaccine protected 100 percent of monkeys from lethal Ebola challenge. Study done with NIH/NIAID. With DRC outbreak declared emergency, $BVAXF is looking at this again. $MRK $AEMD $EBS $REGN $BVAXF

0 · Reply

Market Cap	279.09B
Revenue (ttm)	65.01B
Net Income (ttm)	18.25B
EPS (ttm)	N/A
PE Ratio	20.88
Forward PE	22.13
Profit Margin	28.08%
Debt to Equity Ratio	1.02

Volume	9,241,512
Avg Vol	9,266,106
Day's Range	N/A - N/A
Shares Out	2.47B
Stochastic %K	98%
Beta	0.18
Analysts	Strong Sell
Price Target	$131.56